ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation
Full article: https://www.asco.org/about-asco/press-center/news-releases/asco-releases-rapid-guideline-recommendation-update-certain
The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Are PARP inhibitors recommended for my type of breast cancer?
- Will my insurance pay for PARP inhibitor treatment?
- Should I be tested for an inherited mutation in a BRCA1 or BRCA2 gene or another gene that is linked to breast cancer?
- I have a mutation in a gene other than BRCA1 or BRCA2; would PARP inhibitors be helpful for treating my cancer?
- How long will I have to use PARP inhibitors?
- What are the side effects of PARP inhibitors?
Open Clinical Trials
- NCT04481113- Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer. This phase I trial tests the side effects and best dose of abemaciclib (a kinase inhibitor) and niraparib (a PARP inhibitor) in treating patients with breast cancer that is positive for estrogen or progesterone receptors (hormone receptor-positive [HR+]) and HER2 negative. Giving these two drugs together before surgery may reduce the size of the tumor.
- NCT04584255-Niraparib + TSR042 In BRCA-Mutated Breast Cancer This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA mutations.
- The names of the study drugs involved in this study are:
- Niraparib (Zejula)
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.